There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Esperion (NASDAQ:ESPR) and Myovant Sciences (NYSE:MYOV) with bullish sentiments.
Esperion (ESPR)
Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Esperion today and set a price target of $95. The company’s shares opened today at $40.41, close to its 52-week low of $33.06.
According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 11.9% and a 39.1% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.
Esperion has an analyst consensus of Moderate Buy, with a price target consensus of $73.23.
See today’s analyst top recommended stocks >>
Myovant Sciences (MYOV)
In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Myovant Sciences. The company’s shares opened today at $23.47, close to its 52-week high of $25.54.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 15.7% and a 57.7% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Voyager Therapeutics Inc.
Currently, the analyst consensus on Myovant Sciences is a Moderate Buy with an average price target of $44.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
